- Poster presentation
- Open Access
The many faces of HFPEF: insights from the CMR substudy of DIAMOND-HFPEF
© Kanagala et al; licensee BioMed Central Ltd. 2015
- Published: 3 February 2015
- Myocardial Infarction
- Leave Ventricular Ejection Fraction
- Cardiac Magnetic Resonance
- Hypertrophic Cardiomyopathy
- Cardiac Magnetic Resonance Imaging
Heart failure with preserved ejection fraction (HFPEF) carries significant mortality and morbidity. This population is characterized by marked heterogeneity. To date, this population has been poorly phenotyped and it remains unclear what proportion may have evidence of myocardial infarction (MI), undiagnosed cardiomyopathies or phenocopies of heart failure. At present, echocardiography remains the primary modality for diagnosis and inclusion into randomized controlled trials but can be challenging due to the high prevalence of lung disease, obesity and frailty. We sought to evaluate the impact of adding cardiac magnetic resonance imaging (CMR) to the diagnostic pathway.
CMR was offered as part of DIAMOND-HFPEF (Developing Imaging And plasMa biOmarkers iN Describing Heart Failure with Preserved Ejection Fraction): a prospective, observational, cohort study. Inclusion criteria were: clinical features of HF and left ventricular ejection fraction (LVEF) > 50% as per echocardiography. Exclusion criteria were: suspected or confirmed cardiomyopathy, pericardial constriction, inability to consent, non-cardiovascular life expectancy < 6 months, myocardial infarction in the preceding 6 months, severe valve disease, severe obstructive pulmonary disease (or FEV1 < 30% or FVC < 50% predicted) and estimated glomerular filtration rate < 30 ml/min/m2. 138 eligible subjects underwent 3 T CMR (Siemens Skyra) according to a standardized protocol including cine, first-pass perfusion and late gadolinium imaging. The clinical CMR reports were made available to patients' responsible physicians.
Baseline Clinical and CMR Characteristics
Age (years) 74 ± 10
BMI (kg/m2) 33 ± 8
Male (n, %) 73 (54)
BMI > 35 kg/m2 (n,%) 46 (34)
Sinus Rhythm (n, %) 90 (67)
NYHA class (n, %)
Atrial Fibrillation/Flutter (n, %) 44 (33)
I: 38 (16)
Heart Rate (bpm) 70
II: 51 (40)
Systolic BP (mmHg) 143
III: 41 (31)
Diastolic BP (mmHg) 73
IV: 4 (3)
Diabetes (n, %) 71 (53)
BNP (pg/ml); (median, IQR) 182.3 (166.2, 286.0)
Hypertension (n, %) 125 (93)
Serum Creatinine (µmol/l) 102 ± 34
Coronary Artery Disease (n, %) 27 (20)
LVEF (%) 57 ± 10
Angina (n, %) 26 (19)
LVEDVI (ml/m2) 76 ± 26
COPD/Asthma (n, %) 20/6 (15/4)
LVESVI (ml/m2) 33 ± 14
CMR provides unique insights into etiology, enabling disease-specific management and the potential for tailored therapies to improve outcomes in HFPEF. Furthermore, the frequent finding of HFPEF ‘phenocopies' such as hypertrophic cardiomyopathy and amyloid in our cohort may in part explain the limited efficacy of generic medical therapies in numerous randomized controlled studies.
DIAMOND-HFPEF is funded by the NIHR Leicester Cardiovascular Biomedical Research Unit.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.